Research programme: nuclear receptor-targeting therapeutics - Genfit

Drug Profile

Research programme: nuclear receptor-targeting therapeutics - Genfit

Alternative Names: AD Inov collaborative programme; G-15750; TGFTX1; TGFTX3

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator Genfit
  • Class Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators; Nuclear receptor subfamily 1 group F member 3 antagonists; Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatic fibrosis
  • No development reported Alzheimer's disease; Autoimmune disorders; Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in France
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in France
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top